After @ weeks , there were no significant between-group differences in cough-specific quality of life improvement ( montelukast : @ , @-@ ; placebo : @ , @-@ ; mean difference -@ , -@ to @ , p = @ ) or adverse event rates ( @ ( @ % ) of @ patients on montelukast reported one or more adverse events ; @ ( @ % ) of @ on placebo ; p = @ ) .